Sign up to save your podcasts
Or
Share Signal
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Signal
By StatScience
Signal episodes
- Episode #9 - What should you most fear? Sharks, killer snails or the flu?How do our perceptions of risk, and our outsized — or undersized — fears affect our health? In this episode of Signal we explore the killer snail (flu) and the shark (cancer screening) of medicine.(It's a metaphor, people.)The Signal podcast is produced by Katie Hiler. Illustration by Molly Ferguson for STAT.24 min
- Episode #9 - What should you most fear? Sharks, killer snails or the flu?How do our perceptions of risk, and our outsized — or undersized — fears affect our health? In this episode of Signal we explore the killer snail (flu) and the shark (cancer screening) of medicine.(It's a metaphor, people.)The Signal podcast is produced by Katie Hiler. Illustration by Molly Ferguson for STAT.24 min
- SIgnal takes a mini-break for a special reasonHi, Signal listeners, we have some happy news to share — Meg is getting married! That means we’ll be taking a break for a few weeks, but fear not, Signal will be back in March with fabulous new shows on how our medicines get made. Take a listen to see what’s up next. Spoiler alert: It includes killer snails.4 min
- SIgnal takes a mini-break for a special reasonHi, Signal listeners, we have some happy news to share — Meg is getting married! That means we’ll be taking a break for a few weeks, but fear not, Signal will be back in March with fabulous new shows on how our medicines get made. Take a listen to see what’s up next. Spoiler alert: It includes killer snails.4 min
- Episode #6 - Choosing scientific sides in the fight against Alzheimer'sAlzheimer’s disease poses a huge threat to our health and our economy — more than 5 million Americans are estimated to currently have the disease. But it has been as good at evading treatment as just about any disease out there.For decades, scientists’ efforts in treating Alzheimer's have been focused on a protein in the brain called beta amyloid. Some think that the seeds of the disease’s destruction lie in the protein. But others in the field think that may be a dead end. Who is right?The Signal podcast is produced by Katie Hiler. Illustration by Molly Ferguson for STAT.21 min
- Episode #6 - Choosing scientific sides in the fight against Alzheimer'sAlzheimer’s disease poses a huge threat to our health and our economy — more than 5 million Americans are estimated to currently have the disease. But it has been as good at evading treatment as just about any disease out there.For decades, scientists’ efforts in treating Alzheimer's have been focused on a protein in the brain called beta amyloid. Some think that the seeds of the disease’s destruction lie in the protein. But others in the field think that may be a dead end. Who is right?The Signal podcast is produced by Katie Hiler. Illustration by Molly Ferguson for STAT.21 min
- UPDATE: What happened at the FDA panel review of one Duchenne drug?An FDA panel reviewed a drug for Duchenne muscular dystrophy called drisaperson on Tuesday. What it found is not encouraging. The Signal podcast takes a look at what happened and where things go from here.9 min
- UPDATE: What happened at the FDA panel review of one Duchenne drug?An FDA panel reviewed a drug for Duchenne muscular dystrophy called drisaperson on Tuesday. What it found is not encouraging. The Signal podcast takes a look at what happened and where things go from here.9 min
- Hello, World! It's Signal.An introduction to Signal, a podcast from Stat.(Image: Fox Photos/Getty Images)2 min
- Hello, World! It's Signal.An introduction to Signal, a podcast from Stat.(Image: Fox Photos/Getty Images)2 min
About Signal
From the publisher's feed
The impact of modern medicine on the human condition can’t be underestimated. From antibiotics to vaccines, medicine has changed the way our bodies work, answered deadly questions, and promised faster cures.
But it’s not simple. Drug development is rife with tension. It costs a lot of money, and takes a long time. Most things fail. But when they succeed, they can make a tremendous difference in people’s lives.
Where will the next breakthroughs come from? How will we pay for them? Who decides who gets them?
This is SIGNAL, a podcast from Stat that sorts through the flood of health and medical news to deliver stories of the next development, controversy or breakthrough that will affect us all. Hosted by veteran biotech journalist Luke Timmerman and CNBC biotech and pharma reporter Meg Tirrell, SIGNAL explores the characters and the dramas behind today’s medicine, from biotech boardrooms, to research labs, to your corner pharmacy. Subscribe to us on iTunes and Stitcher, or visit us on our website, www.statnews.com.